New vaccines on the horizon
Perspektive u razvoju profilaktičkih vakcina
Article (Published version)
Metadata
Show full item recordAbstract
Vaccines are considered to be one of the greatest public health achievements of the last century. As a result of widespread vaccine use, the smallpox virus has been completely eradicated and the incidence of other diseases such as polio, measles, tetanus and diphtheria has been drastically reduced. Current licensed vaccines, predominantly composed of either live attenuated or killed pathogens, pathogen subunits, owe their success to their ability to elicit neutralizing antibodies against pathogens. On the other side, cell-mediated immunity, which plays a central role in elimination of intracellular pathogens (which in most cases leads to chronic infections) is much more difficult to obtain using current vaccines. Currently, numerous vector and nucleic acid (DNA and mRNA)-based prophylactic vaccines, capable of inducing substantial vaccine-specific T cell responses, are investigated in preclinical and clinical studies, with promising results. This review focuses the background of vector... and nucleic acid-based vaccines, their strengths and weaknesses and safety issues.
Vakcine se smatraju jednim od najvećih javnozdravstvenih dostignuća prošlog veka. Zahvaljujući vakcinaciji u svetu su potpuno iskorenjene velike boginje, a incidencija drugih infektivnih bolesti, kao što su dečija paraliza, male boginje, tetanus i difterija, drastično je smanjena. Današnje licencirane vakcine, koje pretežno sadrže žive atenuisane ili mrtve patogene ili njihove delove, su uspešne zahvaljujući tome što stimulišu produkciju neutrališućih antitela. Sa druge strane, ove vakcine mnogo teže indukuju ćelijski-posredovanu imunost, koja je važna za eliminaciju intraćelijskih patogena (koji često dovode do hroničnih infekcija). Trenutno se u pretkliničkim i kliničkim studijama ispituju brojne profilaktičke vakcine zasnovane na vektorima i nukleinskim kiselinama (DNK i iRNK), sposobne da indukuju snažan odgovor T-ćelija na vakcinalni antigen, sa obećavajućim rezultatima. U ovom radu su date osnovne informacije o vakcinama sa vektorima i nukleinskim kiselinama, opisani su mehanizmi... kojima one pokreću imunski odgovor, njihove dobre i loše strane, kao i problemi vezani za njihovu bezbednu primenu.
Keywords:
DNA vaccines / MRNA vaccines / Vaccine types / Vector vaccines / tipovi vakcina / vektorske vakcine / DNK vakcine / iRNK vakcineSource:
Arhiv za farmaciju, 2019, 69, 6, 385-405Publisher:
- Beograd : Savez farmaceutskih udruženja Srbije
Funding / projects:
Collections
Institution/Community
PharmacyTY - JOUR AU - Arsenović-Ranin, Nevena PY - 2019 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3556 AB - Vaccines are considered to be one of the greatest public health achievements of the last century. As a result of widespread vaccine use, the smallpox virus has been completely eradicated and the incidence of other diseases such as polio, measles, tetanus and diphtheria has been drastically reduced. Current licensed vaccines, predominantly composed of either live attenuated or killed pathogens, pathogen subunits, owe their success to their ability to elicit neutralizing antibodies against pathogens. On the other side, cell-mediated immunity, which plays a central role in elimination of intracellular pathogens (which in most cases leads to chronic infections) is much more difficult to obtain using current vaccines. Currently, numerous vector and nucleic acid (DNA and mRNA)-based prophylactic vaccines, capable of inducing substantial vaccine-specific T cell responses, are investigated in preclinical and clinical studies, with promising results. This review focuses the background of vector and nucleic acid-based vaccines, their strengths and weaknesses and safety issues. AB - Vakcine se smatraju jednim od najvećih javnozdravstvenih dostignuća prošlog veka. Zahvaljujući vakcinaciji u svetu su potpuno iskorenjene velike boginje, a incidencija drugih infektivnih bolesti, kao što su dečija paraliza, male boginje, tetanus i difterija, drastično je smanjena. Današnje licencirane vakcine, koje pretežno sadrže žive atenuisane ili mrtve patogene ili njihove delove, su uspešne zahvaljujući tome što stimulišu produkciju neutrališućih antitela. Sa druge strane, ove vakcine mnogo teže indukuju ćelijski-posredovanu imunost, koja je važna za eliminaciju intraćelijskih patogena (koji često dovode do hroničnih infekcija). Trenutno se u pretkliničkim i kliničkim studijama ispituju brojne profilaktičke vakcine zasnovane na vektorima i nukleinskim kiselinama (DNK i iRNK), sposobne da indukuju snažan odgovor T-ćelija na vakcinalni antigen, sa obećavajućim rezultatima. U ovom radu su date osnovne informacije o vakcinama sa vektorima i nukleinskim kiselinama, opisani su mehanizmi kojima one pokreću imunski odgovor, njihove dobre i loše strane, kao i problemi vezani za njihovu bezbednu primenu. PB - Beograd : Savez farmaceutskih udruženja Srbije T2 - Arhiv za farmaciju T1 - New vaccines on the horizon T1 - Perspektive u razvoju profilaktičkih vakcina VL - 69 IS - 6 SP - 385 EP - 405 DO - 10.5937/arhfarm1906385A ER -
@article{ author = "Arsenović-Ranin, Nevena", year = "2019", abstract = "Vaccines are considered to be one of the greatest public health achievements of the last century. As a result of widespread vaccine use, the smallpox virus has been completely eradicated and the incidence of other diseases such as polio, measles, tetanus and diphtheria has been drastically reduced. Current licensed vaccines, predominantly composed of either live attenuated or killed pathogens, pathogen subunits, owe their success to their ability to elicit neutralizing antibodies against pathogens. On the other side, cell-mediated immunity, which plays a central role in elimination of intracellular pathogens (which in most cases leads to chronic infections) is much more difficult to obtain using current vaccines. Currently, numerous vector and nucleic acid (DNA and mRNA)-based prophylactic vaccines, capable of inducing substantial vaccine-specific T cell responses, are investigated in preclinical and clinical studies, with promising results. This review focuses the background of vector and nucleic acid-based vaccines, their strengths and weaknesses and safety issues., Vakcine se smatraju jednim od najvećih javnozdravstvenih dostignuća prošlog veka. Zahvaljujući vakcinaciji u svetu su potpuno iskorenjene velike boginje, a incidencija drugih infektivnih bolesti, kao što su dečija paraliza, male boginje, tetanus i difterija, drastično je smanjena. Današnje licencirane vakcine, koje pretežno sadrže žive atenuisane ili mrtve patogene ili njihove delove, su uspešne zahvaljujući tome što stimulišu produkciju neutrališućih antitela. Sa druge strane, ove vakcine mnogo teže indukuju ćelijski-posredovanu imunost, koja je važna za eliminaciju intraćelijskih patogena (koji često dovode do hroničnih infekcija). Trenutno se u pretkliničkim i kliničkim studijama ispituju brojne profilaktičke vakcine zasnovane na vektorima i nukleinskim kiselinama (DNK i iRNK), sposobne da indukuju snažan odgovor T-ćelija na vakcinalni antigen, sa obećavajućim rezultatima. U ovom radu su date osnovne informacije o vakcinama sa vektorima i nukleinskim kiselinama, opisani su mehanizmi kojima one pokreću imunski odgovor, njihove dobre i loše strane, kao i problemi vezani za njihovu bezbednu primenu.", publisher = "Beograd : Savez farmaceutskih udruženja Srbije", journal = "Arhiv za farmaciju", title = "New vaccines on the horizon, Perspektive u razvoju profilaktičkih vakcina", volume = "69", number = "6", pages = "385-405", doi = "10.5937/arhfarm1906385A" }
Arsenović-Ranin, N.. (2019). New vaccines on the horizon. in Arhiv za farmaciju Beograd : Savez farmaceutskih udruženja Srbije., 69(6), 385-405. https://doi.org/10.5937/arhfarm1906385A
Arsenović-Ranin N. New vaccines on the horizon. in Arhiv za farmaciju. 2019;69(6):385-405. doi:10.5937/arhfarm1906385A .
Arsenović-Ranin, Nevena, "New vaccines on the horizon" in Arhiv za farmaciju, 69, no. 6 (2019):385-405, https://doi.org/10.5937/arhfarm1906385A . .
Related items
Showing items related by title, author, creator and subject.
-
COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects
Riad, Abanoub; Schünemann, Holger; Sameh, Attia; Poklepović Peričić, Tina; Franka Žuljević, Marija; Jürisson, Mikk; Kalda, Ruth; Lang, Katrin; Morankar, Sudhakar; Ali Yesuf, Elias; Mekhemar, Mohamed; Danso-Appiah, Anthony; Sofi-Mahmudi, Ahmad; Pérez-Gaxiola, Giordano; Dziedzic, Arkadiusz; Apóstolo, João; Cardoso, Daniela; Marc, Janja; Moreno-Casbas, Mayte; Shey Wiysonge, Charles; Qaseem, Amir; Gryschek, Anna; Tadić, Ivana; Hussain, Salman; Ahmed Khan, Mohammed; Klugarova, Jitka; Pokorna, Andrea; Koščík, Michal; Klugar, Miloslav (MDPI, 2021) -
Sex bias in mouse humoral immune response to influenza vaccine depends on the vaccine type
Živković, Irena; Petrović, Raisa; Arsenović-Ranin, Nevena; Petrusić, Vladimir; Minić, Rajna; Bufan, Biljana; Popović, Olga; Leposavić, Gordana (Academic Press Ltd- Elsevier Science Ltd, London, 2018) -
Developing a quality management tool for preparing Good Distribution Practice audit of pharmaceutical contract vaccine distributor
Bekcić, Stana; Kelecević, Nenad; Marinković, Valentina; Tasić, Ljiljana; Krajnović, Dušanka (Assoc Pharmaceutical Teachers India, Bangalore, 2015)